Trial Profile
Long-term Study of DSP-5423P in Patients With Schizophrenia (Phase 3)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Blonanserin (Primary) ; Blonanserin (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Sumitomo Dainippon Pharma; Sumitomo Pharma
- 08 Mar 2022 Results of post-hoc analysis published in the Progress in Neuro-Psychopharmacology and Biological Psychiatry.
- 27 Dec 2019 Results published in the CNS Drugs
- 10 Sep 2018 According to a Sumitomo Dainippon Pharma media release, data from this trial were presented in a poster presentation at WFSPB 2018 KOBE (WFSBP Asia Pacific Regional Congress of Biological Psychiatry)